Skip to main content
SpringerLink
Log in

Tumor escape mechanisms in prostate cancer

  • Symposium Paper
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Numerous immunotherapy trials have been carried out in prostate cancer (PC) patients, with induction of antigen-specific T cells in some cases. Despite this capability, limited success is seen in terms of tumor regression or survival. In this review, we discuss the evidence for tumor escape strategies that may contribute to vaccine failure in the setting of PC. These include defects in antigen presentation, production of immunosuppressive substances, induction of T cell death, T cell receptor dysfunction, and the presence of tolerogenic dendritic cells and regulatory T cells inside prostate tumors. It is clear that novel strategies aimed at preventing tumor escape, such as small molecular weight inhibitors of immunosuppressive molecules, adoptive transfer of TCR transgenic T cells, removal of Tregs, combined with anti-androgen therapy and prostate-specific vaccines, need to be examined further in PC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Black RJ, Bray F, Ferlay J, Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33:1075–1107

    Article  PubMed  CAS  Google Scholar 

  2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer Statistics, 2005. CA Cancer J Clin 55:10–30

    Article  PubMed  Google Scholar 

  3. Harada M, Noguchi M, Itoh K (2003) Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 8:193–199

    Article  PubMed  CAS  Google Scholar 

  4. Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57:80–92

    Article  PubMed  CAS  Google Scholar 

  5. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R et al (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91:688–694

    PubMed  CAS  Google Scholar 

  6. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P et al (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6:1632–1638

    PubMed  CAS  Google Scholar 

  7. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG (2004) Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94:412–418

    Article  PubMed  CAS  Google Scholar 

  8. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, et al (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160–5168

    PubMed  CAS  Google Scholar 

  9. Vieweg J, Dannull J (2005) Technology insight: vaccine therapy for prostate cancer. Nature Clinical Practice Urology 2:44–51

    Article  PubMed  CAS  Google Scholar 

  10. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353–362

    Article  PubMed  CAS  Google Scholar 

  11. Pawelec G (2004) Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 53:262–274

    Article  PubMed  CAS  Google Scholar 

  12. Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844–854

    Article  PubMed  Google Scholar 

  13. Humphrey P (2003) Prostate pathology: American society clinical Pathology

  14. Megalli MR, Gursel EO, Veenema RJ (1973) Ascites as an unusual presentation of carcinoma of the prostate. J Urol 110:232–234

    PubMed  CAS  Google Scholar 

  15. Ozenci V, Miller AM, Palmborg A, Egevad L, Jaremko GA, Kalkner KM, Pisa P (2005) Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer. Prostate 65:20–26

    Article  PubMed  Google Scholar 

  16. Vesalainen S, Lipponen P, Talja M, Syrjanen K (1994) Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30A:1797–1803

    Article  PubMed  CAS  Google Scholar 

  17. Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N (1999) High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 54:467–472

    Article  PubMed  CAS  Google Scholar 

  18. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA (2004) The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91:541–543

    Article  PubMed  CAS  Google Scholar 

  19. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW (1995) Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87:280–285

    PubMed  CAS  Google Scholar 

  20. Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P (1997) MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33:233–239

    Article  PubMed  CAS  Google Scholar 

  21. Abdul M, Hoosein N (2000) Changes in beta-2 microglobulin expression in prostate cancer. Urol Oncol 5:168–172

    Article  PubMed  CAS  Google Scholar 

  22. Lee HM, Timme TL, Thompson TC (2000) Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 60:1927–1933

    PubMed  CAS  Google Scholar 

  23. Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C (1989) Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 86:6719–6723

    Article  PubMed  CAS  Google Scholar 

  24. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46:681–686; discussion 686–687

    Google Scholar 

  25. Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson RR, Robinson N, Pyka R, Liu Y, Zheng P (2003) Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 3:2

    PubMed  Google Scholar 

  26. Kidd P (2003) Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8:223–246

    PubMed  Google Scholar 

  27. Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM (2000) Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44:271–274

    Article  PubMed  CAS  Google Scholar 

  28. Wise GJ, Marella VK, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164:722–725

    Article  PubMed  CAS  Google Scholar 

  29. Elsasser-Beile U, Gierschner D, Jantscheff P, Schultze-Seemann W, Katzenwadel A, Wetterauer U (2003) Different basal expression of type T1 and T2 cytokines in peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Anticancer Res 23:4027–4031

    PubMed  Google Scholar 

  30. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161:182–187

    Article  PubMed  CAS  Google Scholar 

  31. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41:127–133

    Article  PubMed  CAS  Google Scholar 

  32. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702–2706

    PubMed  CAS  Google Scholar 

  33. Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95:497–505

    Article  PubMed  CAS  Google Scholar 

  34. Perambakam SM, Srivastava R, Peace DJ (2005) Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate cancer. Clin Immunol 117:94–99

    Article  PubMed  CAS  Google Scholar 

  35. Elsasser-Beile U, Przytulski B, Gierschner D, Grussenmeyer T, Katzenwadel A, Leiber C, Deckart A, Wetterauer U (2000) Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Prostate 45:1–7

    Article  PubMed  CAS  Google Scholar 

  36. Cardillo MR, Petrangeli E, Perracchio L, Salvatori L, Ravenna L, Di Silverio F (2000) Transforming growth factor-beta expression in prostate neoplasia. Anal Quant Cytol Histol 22:1–10

    PubMed  CAS  Google Scholar 

  37. Stravodimos K, Constantinides C, Manousakas T, Pavlaki C, Pantazopoulos D, Giannopoulos A, Dimopoulos C (2000) Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters. Anticancer Res 20:3823–3828

    PubMed  CAS  Google Scholar 

  38. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM (2004) Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10:1992–1999

    Article  PubMed  CAS  Google Scholar 

  39. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, Chang TS (1995) Characterization and localization of nitric oxide synthase in the human prostate. Urology 45:435–439

    Article  PubMed  CAS  Google Scholar 

  40. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K (1997) Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 33:1–8

    Article  PubMed  CAS  Google Scholar 

  41. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M Harkonen P (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29:23–28

    Article  PubMed  CAS  Google Scholar 

  42. Wang J, Torbenson M, Wang Q, Ro JY, Becich M (2003) Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol Oncol 21:117–122

    PubMed  Google Scholar 

  43. Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82:1897–1903

    Article  PubMed  CAS  Google Scholar 

  44. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F et al (2005) Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201(8):1257–1268

    Article  PubMed  CAS  Google Scholar 

  45. Harris BE, Pretlow TP, Bradley EL Jr, Whitehurst GB, Pretlow TG II (1983) Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma. Cancer Res 43:3008–3012

    PubMed  CAS  Google Scholar 

  46. Aaltoma SH, Lipponen PK, Kosma VM (2001) Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 21:3101–3106

    PubMed  CAS  Google Scholar 

  47. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311–320

    Article  PubMed  Google Scholar 

  48. Bronte V, Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641–654

    Article  PubMed  CAS  Google Scholar 

  49. Mellor A (2005) Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 338:20–24

    Article  PubMed  CAS  Google Scholar 

  50. Kirschenbaum A, Liu X, Yao S, Levine AC (2001) The role of cyclooxygenase-2 in prostate cancer. Urology 58:127–131

    Article  PubMed  CAS  Google Scholar 

  51. Wang W, Bergh A, Damber JE (2005) Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11:3250–3256

    Article  PubMed  CAS  Google Scholar 

  52. Badawi AF (2000) The role of prostaglandin synthesis in prostate cancer. BJU Int 85:451–462

    Article  PubMed  CAS  Google Scholar 

  53. Chan AK, Lockhart DC, von Bernstorff W, Spanjaard RA, Joo HG, Eberlein TJ, Goedegebuure PS (1999) Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int J Cancer 82:721–726

    Article  PubMed  CAS  Google Scholar 

  54. Rughetti A, Pellicciotta I, Biffoni M, Backstrom M, Link T, Bennet EP, Clausen H, Noll T, Hansson GC, Burchell JM et al (2005) Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 174:7764–7772

    PubMed  CAS  Google Scholar 

  55. Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC (1999) MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol 3:163–168

    PubMed  Google Scholar 

  56. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U et al (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811–816

    Article  PubMed  CAS  Google Scholar 

  57. Arai T, Fujita K, Fujime M, Irimura T (2005) Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol 12:654–661

    Article  PubMed  CAS  Google Scholar 

  58. Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJ, Vuckovic S, Hart DN (2002) Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. J Urol 168:741–747

    Article  PubMed  CAS  Google Scholar 

  59. Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, Shurin GV, Shurin MR (2003) Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol 170:2026–2030

    Article  PubMed  CAS  Google Scholar 

  60. Abrams SI (2005) Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. Front Biosci 10:809–821

    PubMed  CAS  Google Scholar 

  61. Furuya Y, Fuse H, Masai M (2001) Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res 21:3595–3598

    PubMed  CAS  Google Scholar 

  62. Liu QY, Rubin MA, Omene C, Lederman S, Stein CA (1998) Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res 4:1803–1811

    PubMed  CAS  Google Scholar 

  63. Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP (2005) Tumor exosomes expressing Fas ligand mediate CD8(+) T-cell apoptosis. Blood Cells Mol Dis 35:169–173

    Article  PubMed  CAS  Google Scholar 

  64. Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP (1999) Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 162:3273–3279

    PubMed  CAS  Google Scholar 

  65. Restifo NP (2000) Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6:493–495

    Article  PubMed  CAS  Google Scholar 

  66. Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr, Schellhammer PF, Glass WF, Somers KD (2004) Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J Immunother 27:13–26

    Article  PubMed  CAS  Google Scholar 

  67. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, Bolton WE (1998) Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32:109–119

    Article  PubMed  CAS  Google Scholar 

  68. Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL (2002) Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br J Cancer 86:168–178

    Article  PubMed  CAS  Google Scholar 

  69. Peggs KS, Allison JP (2005) Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol 130:809–824

    Article  PubMed  CAS  Google Scholar 

  70. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP (1997) Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94:8099–8103

    Article  PubMed  CAS  Google Scholar 

  71. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444–2448

    PubMed  CAS  Google Scholar 

  72. Hull GW, McCurdy MA, Nasu Y, Bangma CH, Yang G, Shimura S, Lee HM, Wang J, Albani J, Ebara S, et al (2000) Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7–1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 6:4101–4109

    PubMed  CAS  Google Scholar 

  73. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252

    Article  PubMed  CAS  Google Scholar 

  74. Lutz MB, Schuler G (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 23:445–449

    Article  PubMed  CAS  Google Scholar 

  75. Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13–27

    Article  PubMed  CAS  Google Scholar 

  76. Troy A, Davidson P, Atkinson C, Hart D (1998) Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol 160:214–219

    Article  PubMed  CAS  Google Scholar 

  77. Aalamian M, Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E, Huland H, Shurin MR (2001) Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46:68–75

    Article  PubMed  CAS  Google Scholar 

  78. Shurin GV, Aalamian M, Pirtskhalaishvili G, Bykovskaia S, Huland E, Huland H, Shurin MR (2001) Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors. Eur Urol 39 Suppl 4:37–40

    Article  Google Scholar 

  79. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ et al (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36:39–44

    Article  PubMed  CAS  Google Scholar 

  80. Barrou B, Benoit G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S, Massicard S, Bercovici N, Ericson ML, Thiounn N (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53:453–460

    Article  PubMed  Google Scholar 

  81. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894–3903

    PubMed  CAS  Google Scholar 

  82. Antony PA, Restifo NP (2002) Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25:202–206

    Article  PubMed  CAS  Google Scholar 

  83. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164

    PubMed  CAS  Google Scholar 

  84. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32

    Article  PubMed  CAS  Google Scholar 

  85. Tien AH, Xu L, Helgason CD (2005) Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res 65:2947–2955

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Experimental work in our laboratory is supported partly by grants from the Cancer Society in Stockholm, the Swedish Cancer Society, Karolinska Institute Funds, the EU 6-FP “ALLOSTEM” (LSHB-CT-2004-503319), the EU 6-FP “ENACT”, and U.S. Department of Defense Prostate Cancer Research Program (PC030958).

Author information

Authors and Affiliations

  1. Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, 171 76, Stockholm, Sweden

    Ashley M. Miller & Pavel Pisa

Authors
  1. Ashley M. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pavel Pisa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashley M. Miller.

Additional information

This article is a symposium paper from the conference Progress in Vaccination against Cancer 2005 (PIVAC 5), held in Athens, Greece, on 20–21 September 2005.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, A.M., Pisa, P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 56, 81–87 (2007). https://doi.org/10.1007/s00262-005-0110-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0110-x

Keywords

Search

Navigation